PMID- 21478255 OWN - NLM STAT- MEDLINE DCOM- 20110831 LR - 20231213 IS - 1522-1504 (Electronic) IS - 1040-0605 (Print) IS - 1040-0605 (Linking) VI - 301 IP - 1 DP - 2011 Jul TI - Thirdhand smoke: a new dimension to the effects of cigarette smoke on the developing lung. PG - L1-8 LID - 10.1152/ajplung.00393.2010 [doi] AB - The underlying mechanisms and effector molecules involved in mediating in utero smoke exposure-induced effects on the developing lung are only beginning to be understood. However, the effects of a newly discovered category of smoke, i.e., thirdhand smoke (THS), on the developing lung are completely unknown. We hypothesized that, in addition to nicotine, other components of THS would also affect lung development adversely. Fetal rat lung explants were exposed to nicotine, 1-(N-methyl-N-nitrosamino)-1-(3-pyridinyl)-4-butanal (NNA), or 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), the two main tobacco-specific N-nitrosamine constituents of THS, for 24 h. We then determined key markers for alveolar paracrine signaling [epithelial differentiation markers surfactant phospholipid and protein synthesis; mesenchymal differentiation markers peroxisome proliferator-activated receptor gamma (PPAR-gamma), fibronectin and calponin], the BCL-2-to-Bax ratio (BCL-2/Bax), a marker of apoptosis and the involvement of nicotinic acetylcholine receptors (nAChR)-alpha3 and -alpha7 in mediating NNA's and NNK's effects on the developing lung. Similar to the effects of nicotine, exposure of the developing lung to either NNK or NNA resulted in disrupted homeostatic signaling, indicated by the downregulation of PPAR-gamma, upregulation of fibronectin and calponin protein levels, decreased BCL-2/Bax, and the accompanying compensatory stimulation of surfactant phospholipid and protein synthesis. Furthermore, nAChR-alpha3 and -alpha7 had differential complex roles in mediating these effects. NNK and NNA exposure resulted in breakdown of alveolar epithelial-mesenchymal cross-talk, reflecting lipofibroblast-to-myofibroblast transdifferentiation, suggesting THS constituents as possible novel contributors to in utero smoke exposure-induced pulmonary damage. These data are particularly relevant for designing specific therapeutic strategies, and for formulating public health policies to minimize THS exposure. FAU - Rehan, Virender K AU - Rehan VK AD - Departments of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California 90502, USA. vrehan@labiomed.org FAU - Sakurai, Reiko AU - Sakurai R FAU - Torday, John S AU - Torday JS LA - eng GR - HD51857/HD/NICHD NIH HHS/United States GR - HD058948/HD/NICHD NIH HHS/United States GR - R01 HD051857/HD/NICHD NIH HHS/United States GR - HL75405/HL/NHLBI NIH HHS/United States GR - R01 HD051857-03/HD/NICHD NIH HHS/United States GR - HL55268/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20110408 PL - United States TA - Am J Physiol Lung Cell Mol Physiol JT - American journal of physiology. Lung cellular and molecular physiology JID - 100901229 RN - 0 (Aldehydes) RN - 0 (Bungarotoxins) RN - 0 (Calcium-Binding Proteins) RN - 0 (Microfilament Proteins) RN - 0 (Nitrosamines) RN - 0 (PPAR gamma) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Receptors, Nicotinic) RN - 0 (Tobacco Smoke Pollution) RN - 6EE945D3OK (Mecamylamine) RN - 6M3C89ZY6R (Nicotine) RN - 7S395EDO61 (4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone) RN - H21352682A (butyraldehyde) SB - IM MH - Aldehydes/toxicity MH - Animals MH - Apoptosis/drug effects MH - Bungarotoxins/pharmacology MH - Calcium-Binding Proteins/metabolism MH - Lung/*drug effects/*embryology/pathology MH - Mecamylamine/pharmacology MH - Microfilament Proteins/metabolism MH - Nicotine/toxicity MH - Nitrosamines/toxicity MH - PPAR gamma/metabolism MH - Proto-Oncogene Proteins c-bcl-2/metabolism MH - Rats MH - Rats, Sprague-Dawley MH - Receptors, Nicotinic/metabolism MH - Smoking/*adverse effects MH - Tobacco Smoke Pollution/*adverse effects MH - Calponins PMC - PMC3129897 EDAT- 2011/04/12 06:00 MHDA- 2011/09/01 06:00 PMCR- 2012/07/01 CRDT- 2011/04/12 06:00 PHST- 2011/04/12 06:00 [entrez] PHST- 2011/04/12 06:00 [pubmed] PHST- 2011/09/01 06:00 [medline] PHST- 2012/07/01 00:00 [pmc-release] AID - ajplung.00393.2010 [pii] AID - L-00393-2010 [pii] AID - 10.1152/ajplung.00393.2010 [doi] PST - ppublish SO - Am J Physiol Lung Cell Mol Physiol. 2011 Jul;301(1):L1-8. doi: 10.1152/ajplung.00393.2010. Epub 2011 Apr 8.